Nuveen Asset Management, LLC Kinnate Biopharma Inc. Transaction History

Nuveen Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $57,916 - $133,577	-16,739 Reduced 16.96%	81,967 $512,000
Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $64,945 - $150,509	-12,347 Reduced 11.12%	98,706 $602,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $315 - $504	-32 Reduced 0.03%	111,053 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $142,210 - $248,820	19,140 Added 20.82%	111,085 $1.4 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $15,993 - $37,221	2,069 Added 2.3%	91,945 $925,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $95,040 - $146,764	-5,760 Reduced 6.02%	89,876 $1.59 Million
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $674,874 - $942,398	37,893 Added 65.62%	95,636 $2.2 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $189,879 - $269,973	8,557 Added 17.4%	57,743 $1.34 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $1.33 Million - $1.97 Million	49,186 New	49,186 $1.53 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.